期刊
INFLAMMATORY BOWEL DISEASES
卷 27, 期 7, 页码 1107-1115出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izaa258
关键词
inflammatory bowel disease; medications; atherosclerosis; cardiovascular risk
Patients with chronic inflammatory disorders have an increased risk of cardiovascular disease, with certain medications potentially reducing inflammation but also posing risks for cardiovascular issues.
There is increased risk of cardiovascular disease in patients with chronic inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Studies have shown association between cardiovascular disease (eg, myocardial infarction, heart failure, stroke) and inflammatory bowel disease. Medications such as infliximab and adalimumab (monoclonal antibodies to tumor necrosis factor alpha) may help decrease the inflammatory burden and cardiovascular risk; however, there have been reports of hypertriglyceridemia and worsening of moderate to severe heart failure with these medications. Janus kinase inhibitors, such as tofacitinib, have been associated with hyperlipidemia and thromboembolism. We aim to discuss clinical and imaging modalities to assess cardiovascular risk in inflammatory bowel disease patients and review the role of various medications with respect to cardiovascular disease in this population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据